Hutchison China MediTech (Chi-Med) announced the start of a US Phase I bridging trial of its lead drug, fruquintinib, in patients with solid tumor cancers. Fruquintinib is a VEGFR inhibitor with an anti-angiogenesis mechanism. In China, Chi-Med has completed all three clinical trial phases of fruquintinib and filed for market approval in colorectal cancer patients. In 2013, Lilly partnered China rights to fruquintinib with Chi-Med in an $86 million deal, though so far, it has not extended that agreement to the rest of the world.
Source: China Biotoday
